Review

Risks of Transfusion

Authors: Jerry E. Squires, MD, PhD

Abstract

Each year, more than 4 million patients receive a blood transfusion in the United States to control symptoms associated with anemia, coagulopathy, thrombocytopenia, or some combination thereof. In each of these cases, the physician and the patient must weigh the potential benefits of the transfusion along with the associated risks. To assess accurately the risk:benefit ratio and to discuss this with the patient, the physician must be familiar with the range of adverse transfusion outcomes and the current estimates of their frequency. Most important, during the past decade the risk profile of transfusion has changed significantly. Transfusion-transmitted disease, although still a rare outcome of transfusion, is no longer an overriding concern in transfusion safety considerations; however, risks such as hemolysis, transfusion-related lung injury, and anaphylaxis continue to represent significant concerns and are relatively more common than the transmission of infectious diseases after transfusion. Against this background, the development of a national hemovigilance system, designed to evaluate more accurately transfusion adverse outcomes in the United States, will require greater precision and reliability in the assessment of adverse transfusion outcomes by clinicians if the proposed benefits of this system are to be realized.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. US Biovigilance Network [AABB Web site]. Available at: http://www.aabb.org/programsservices/biovigilance. Accessed February 10, 2010.
 
2. Leiby D. Making sense of malaria. Transfusion 2007;47:1573-1577.
 
3. Gubernot DM, Lucey CT, Lee, KC, et al. Babesiosis infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infects Dis 2009;48:25-30.
 
4. Williams AE, Orton SL. "There's something about blood": a scientific perspective on blood donor qualification, in Stramer SL (ed). Blood Safety in the New Millennium. Bethesda, MD, American Association of Blood Banks, 2001:1-32.
 
5. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. JAMA 1997;277:967-972.
 
6. Kleinman S, Busch MP. General overview of transfusion transmitted infections, in Petz LD, Swisher SN, Kleinman S, et al (eds). Clinical Practice of Transfusion Medicine. New York, Churchill-Livingstone, 1996.
 
7. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-768.
 
8. Busch MP. Closing the window on viral transmission by blood transfusion, in Stramer SL (ed). Blood Safety in the New Millennium. Bethesda, MD, American Association of Blood Banks, 2001.
 
9. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005;45:254-264.
 
10. Dodd RY. The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419-421.
 
11. Bihl F, Castelli D, Marincola F, et al. Transfusion-transmitted infections. J Transl Med 2007;5:1-11.
12. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49:1S-29S.
13. Park YA, Brecker ME. Bacterial contamination of blood products, in Simon TL, Snyder EL, Solheim BG, et al (ed). Rossi's Principles of Transfusion Medicine. Chichester, UK, Wiley-Blackwell, 2009.
14. Hillyer CD, Josephson CD, Blajchman MA, et al. Bacterial contamination of blood products: risks, strategies, and regulation. Hematology 2003: American Society of Hematology Educational Program Book. Washington, DC: American Society of Hematology; 2003: 575-589.
15. Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007;47:1134-1142.
16. Mazzei CA, Popovsky MA, Kopko PM. Noninfectious complications of blood transfusion, in Roback JD, Combs MR, Grossman BJ, et al (eds). AABB Technical Manual. Bethesda, MD, AABB, 2008.
17. Strauss RA, Gloster ES, Shanfield MS, et al. Anaphylactic transfusion reactions associated with a possible anti-A2m(1). Clin Lab Haematol 1983;5:371-377.
18. Shimada E, Tadokoro K, Watanabe Y, et al. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002;42:766-773.
19. Greenberger PA. Plasma anaphylaxis and immediate type reactions. in Rossi EC, Simon TL, Moss GS (ed). Principles of Transfusion Medicine. Baltimore, MD, Williams and Wilkins, 1991:635-639.
20. Sazama K. Reports of 355 transfusion-associated deaths: 1976-1985. Transfusion 1990;30:583-590.
21. Linden JV, Wagner K, Voytovich AE, et al. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2000;40:1207-1213.
22. Davenport RD. Hemolytic transfusion reactions, in Simon TL, Snyder, EL, Solheim BG, et al. Rossi's Principles of Transfusion Medicine. Chichester, UK, Wiley-Blackwell, 2009;811-825.
23. Bruno DS, Herman JH. Acute hypotensive transfusion reactions. Lab Med 2006;37:542-545.
24. Arnold DM, Hume HA. Hypotensive transfusion reactions, in Popovsky MA (ed). Transfusion Reactions. Bethesda, MD, AABB Press, 2007;251-273.
25. De Rie MA, van der Plas-van Dalen CM, Engelfriet CP, et al. The serology of febrile transfusion reactions. Vox Sang 1985;49:126-134.
26. Heddle NM, Klama L, Singer J, et al. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-628.
27. Pomper GJ. Febrile, allergic, and nonimmune transfusion reactions. in Simon TL, Snyder EL, Solheim BG, et al. (eds). Rossi's Principles of Transfusion Medicine. Chichester, UK, Wiley-Blackwell, 2009:826-846.
28. Yazer MH, Podlosky L, Clarke G, et al. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004;44:10-15.
29. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44: 774-789.
30. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med 2007;131:708-718.
31. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003;101:454-462.
32. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2009. March 22, 2010. Available at: http://www.fda.gov/biologicsbloodvaccines/safetyavailability/reportaproblem/transfusiondonationfatalities. Accessed February 21, 2011.
33. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009;49:1825-1835.
34. Chapman CE, Stainsby D, Jones H, et al. Serious hazards of transfusion steering group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009;49:440-452.
35. Eder AF, Herron RM, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010;50:1732-1742.
36. Marriott HL, Kekwick A. Volume and rate in blood transfusion for the relief of anaemia. British Medical Journal 1940;1:1043-1046.
37. Zhou L, Giacherion D, Cooling L, et al. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion associated circulatory overload. Transfusion 2005;45:1056-1063.
38. Le G, Daniels CE, Kojicic M, et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. Transfusion 2009;49:13-20.
39. Bux J, Sachs UJH. Pulmonary transfusion reactions. Transfus Med Hemother 2008;35:337-345.
40. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999;39:763-771.
41. Schonewille H, van de Watering LMG, Brand A. Additional red blood cell alloantibodies after blood transfusion in nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006;46:630-635.
42. Vamvakas EC, Pineda AA, Reisner R, et al. The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion 1995;35:26-32.
43. McFarland JG. Posttransfusion purpura, in Papovsky MA (ed). Transfusion Reactions. Bethesda, MD, AABB Press, 2007:275-299.
44. Shulman NR, Aster RH, Leitner A, et al. Immunoreactions involving platelets. V. Post-transfusion purpura due to complement fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in autoimmunity. J Clin Invest 1961;40:1597-1620.
45. Shulman NR, Jordan JV. Platelet immunology, in Coleman RW, Hirsch J, Marder VJ, et al. (eds). Hemostasis and Thrombosis. Philadelphia, PA, Lippincott, 1982:247-342.
46. Dwyre DM, Holland PV. Transfusion-associated graft-versus-host disease. Vox Sang 2008;95:85-93.
47. Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol 2002;117:275-287.
48. Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993;33:742-750.
49. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006;20:273-282.